Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | liver cancer |
| ICD-0-3 | C22.0 |
| Methods | RT-PCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP |
| Sample | liver cancer tissue, liver cancer cell line (Hep3B) |
| Expression Pattern | down-regulated |
| Function Description | Mechanistically, MEG3 promotes the expression and maturition of miR122 which targets PKM2.Therefore,MEG3 decreases the expression and nuclear location of PKM2 dependent on miR122.Furthermore,MEG3 also inhibits CyclinD1 and C-Myc via PKM2 in liver cancer cells.On the other hand,MEG3 promotes B-catenin degradation through ubiquitin-proteasome system dependent on PTEN. Strikingly, MEG3 inhibits B-catenin activity through PKM2 reduction and PTEN increase.Significantly,we also found that excessive B-catenin abrogated the effect of MEG3 in liver cancer.MEG3 overexpression increased the PTEN 3-UTR mRNA methylation compared to control. MEG3 may be an underlying therapeutic target for LUAD functioning as ceRNAs for the regulation of miRNA-mRNA in lung adenocarcinoma. |
| Pubmed ID | 29449541 |
| Year | 2018 |
| Title | Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting B-catenin by activating PKM2 and inactivating PTEN. |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for liver cancer | OMIM COSMIC |